The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Camrelizumab plus famitinib malate in patients with advanced renal cell cancer and unresectable urothelial carcinoma: A multicenter, open-label, single-arm, phase II trial.
 
Yuan-Yuan Qu
No Relationships to Disclose
 
Hongqian Guo
No Relationships to Disclose
 
Hong Luo
No Relationships to Disclose
 
Qing Zou
No Relationships to Disclose
 
Ninazeng Xing
No Relationships to Disclose
 
Zhongquan Sun
No Relationships to Disclose
 
Xuepei Zhang
No Relationships to Disclose
 
Shujie Xia
No Relationships to Disclose
 
Chaohong He
No Relationships to Disclose
 
Hailiang Zhang
No Relationships to Disclose
 
Jinling Cai
No Relationships to Disclose
 
Xiao Zhang
No Relationships to Disclose
 
Quanren Wang
No Relationships to Disclose
 
Dingwei Ye
No Relationships to Disclose